Datopotamab deruxtecan

About

Therapy type: Targeted therapy

Therapy strategy: Topoisomerase inhibition, Trop-2 directed antibody

Mappings

NCI Thesaurus: Datopotamab Deruxtecan (ncit:C151967)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) EGFR somatic variants Non-Small Cell Lung Cancer Datopotamab deruxtecan
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Datopotamab deruxtecan
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Datopotamab deruxtecan
Sensitivity (+) EGFR p.T790M Non-Small Cell Lung Cancer Datopotamab deruxtecan
Sensitivity (+) EGFR Exon 20 (Insertion) Invasive Breast Carcinoma Datopotamab deruxtecan
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan
Sensitivity (+) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
Sensitivity (+) EGFR somatic variants Non-Small Cell Lung Cancer Datopotamab deruxtecan
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Datopotamab deruxtecan
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Datopotamab deruxtecan
Sensitivity (+) EGFR p.T790M Non-Small Cell Lung Cancer Datopotamab deruxtecan
Sensitivity (+) EGFR Exon 20 (Insertion) Invasive Breast Carcinoma Datopotamab deruxtecan
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan